Neoadjuvant therapy with immune checkpoint inhibitors in operable nonsmall cell lung cancer

What is it about?

In localized nonsmall cell lung cancer (NSCLC) systemic recurrences after surgery are common. Therefore, adjuvant or neoadjuvant chemotherapy is used. With the advent of immune checkpoint inhibitors (ICIs) in metastatic disease the question is whether ICIs can further improve the outcome. The relevant literature about neoadjuvant and perioperative use of immune-checkpoint is presented and analysed. Neoadjuvant and perioperative immunochemotherapy improves MPR and EFS rates, especially in more advanced tumours and tumours expressing PD-L1 -- without relevantly increasing toxicities. But further and longer evaluation is needed.

Featured Image